ReviewCalcified tissue international2021
Bone Fragility Fractures in CKD Patients.
Review in Calcified tissue international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Effects of anti-osteoporotic drugs in patients with chronic kidney disease: a systemic review and network meta-analysis of bone mineral density, clinical fracture rate and renal function.Frontiers in pharmacology · 2025Pooled it
- Article
- Impact of denosumab on bone high-resolution peripheral quantitative computed tomography in hemodialysis patients: a retrospective longitudinal observational study.Clinical kidney journal · 2026Article
- Mineral and Bone Disease in CKD and Kidney Transplantation: Controversies, Gaps, and a Path Forward.Kidney international reports · 2026Review
- Synergistic effects of diabetic neuropathy and kidney function decline on second metatarsal skeletal health and foot function: a pilot study.JBMR plus · 2026Article
- Calcium-sensing receptor genetic variants and their association with CKD-MBD in South Indian Tamils.Journal of applied genetics · 2026Article
- PTH Analog Therapy in CKD G4-G5D: Current Evidence and Potential Role of Abaloparatide in Adynamic Bone Disease.Journal of clinical medicine · 2025Review
- Bone-Ti-Alloy Interaction in Hip Arthroplasty of Patients with Diabetes, Dyslipidaemia, and Kidney Dysfunction: Three Case Reports and Brief Review.Medicina (Kaunas, Lithuania) · 2025Review
- Femoral artery calcification predicts hip fracture in maintenance hemodialysis patients.Archives of osteoporosis · 2025Article
- Subtotal versus total parathyroidectomy: retrospective patient-centric outcomes in a chronic dialysis population.BMC nephrology · 2025Observational
- F2-Isoprostanes Are Associated With Increased Fracture Risk in Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Observational
- Relation between bone mineral density and oxidative stress in Egyptian patients with chronic kidney disease: a cross sectional study.BMC nephrology · 2025Article
- Article
- Article
- Bilateral Olecranon and Left Lesser Trochanter Avulsion Fractures in Renal Osteodystrophy: A Rare Case Report and Comprehensive Review.Acta medica Lituanica · 2025Article
- Practice patterns on the management of secondary hyperparathyroidism in the United States: Results from a modified Delphi panel.PloS one · 2025Article
- Effects of bone metabolism on hematopoiesis: A Mendelian randomization study.Osteoporosis and sarcopenia · 2024Article
- The Management of Osteoporosis in Chronic Kidney Disease: A Review of Diagnostic and Therapeutic Approaches.Cureus · 2024Review
- The impact of population ageing on the burden of chronic kidney disease.Nature reviews. Nephrology · 2024Review
- New triple therapy for the diagnosis of CKD-MBD: a cross-sectional study in Shanxi province.BMJ open · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney diseases (CKD) are associated with mineral and bone diseases (MBD), including pain, bone loss, and fractures. Bone fragility related to CKD includes the risk factors observed in osteoporosis in addition to those related to CKD, resulting in a higher risk of mortality related to fractures. Unawareness of such complications led to a poor management of fractures and a lack of preventive approaches. The current guidelines of the Kidney Disease Improving Global Outcomes (KDIGO) recommend the assessment of bone mineral density if results will impact treatment decision. In addition to bone density, circulating biomarkers of mineral, serum bone turnover markers, and imaging techniques are currently available to evaluate the fracture risk. The purpose of this review is to provide an overview of the epidemiology and pathogenesis of CKD-associated bone loss. The contribution of the current tools and other techniques in development are discussed. We here propose a current view of how to better predict bone fragility and the therapeutic options in CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.